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Abstract 
The toxicity of most drugs and chemicals is associated with their enzymatic onversion to toxic metabolites. Bioactivation reactions 
occur in a range of organs and organelles, including mitochondria. The toxicity of haloalkene-derived cysteine S-conjugates and related 
4-thiaalkanoates is associated with their mitochondrial bioactivation. Toxic cysteine S-conjugates are formed by the glutathione 
S-transferase-catalyzed addition of glutathione to haloalkenes to give glutathione S-conjugates, which are hydrolyzed by y-glutamyltrans- 
ferase and dipeptidases. Mitochondrial cysteine conjugate /3-1yase-catalyzed bioactivation of cysteine S-conjugates affords unstable 
a-halothiolates. Haloalkene-derived 4-thiaalkanoates, which are analogs of cysteine S-conjugates that lack an a-amino group, undergo 
bioactivation by the enzymes of fatty acid /3-oxidation to give 3-hydroxy-4-thiaalkanoates that eliminate a-halothiolates, a-Halothiolates 
yield alkylating and acylating agents that interact with cellular macromolecules and thereby cause cell damage. Mitochondrial dysfunction 
is the hallmark of cysteine S-conjugate-induced cytotoxicity: decreased respiration, decreased ATP and total adenine nucleotide 
concentrations, depletion of the mitochondrial glutathione content, perturbations in cellular Ca 2+ homeostasis, and damage to the 
mitochondrial genome are seen with cysteine S-conjugates. Similar changes are observed with cytotoxic 4-thiaalkanoates, but inhibition 
of the medium-chain acyl-CoA dehydrogenase and hypoglycemia are also observed. 
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1. Introduction 
Many synthetic and naturally occurring chemicals in- 
duce mitochondrial dysfunction, and some of these chemi- 
cals have become established as tools in exploring mito- 
chondrial biochemistry. The concept that environmental 
contaminants may also induce mitochondrial dysfunction 
has received little attention. Although the bioactivation of 
xenobiotics is most often associated with the cytochromes 
P-450 located in the hepatic endoplasmic reticulum [1], 
bioactivation reactions occur in several organs and or- 
ganelles. For example, the mutagenicity of vicinal di- 
haloalkanes i associated with hepatic ytosolic glutathione 
S-transferase-catalyzed bioactivation [2], the formation of 
reactive acyl glucuronides from nonsteroidal ntiinflamma- 
tory agents is catalyzed by the microsomal glucuronyl 
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transferases [3,4], and some carcinogens are bioactivated 
by cytosolic sulfotransferases [5,6]. The mitochondrion is
also a site of bioactivation reactions: astrocytic monoamine 
oxidases, which are located in the mitochondrial outer 
membrane, catalyze the oxidation of 1-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine (MPTP) to 1-methyl-4-phenyl- 
2,3-dihydropyridinium (MDTP) [7], which undergoes fur- 
ther oxidation to 1-methyl-4-phenylpyridinium (MPP+); 
MPP + is taken up by the catecholamine transporter of 
dopaminergic neurons [8] and inhibits Complex I of the 
mitochondrial electron transport chain [9]. 
This review will focus on the mitochondrial bioactiva- 
tion and toxicity of cysteine S-conjugates and related 
4-thiaalkanoates. Haloalkene-derived cysteine S-conjugates 
are potent and selective nephrotoxins in vivo and are 
cytotoxic in isolated rat renal proximal tubular cells and in 
cultured cell lines of renal origin (LLC-PK1). 4-Thiaal- 
kanoates are analogs of cysteine S-conjugates that lack the 
a-amino group and are nephrotoxic and hepatotoxic in 
vivo and cytotoxic in isolated rat hepatocytes. 
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2. Mitochondrial bioactivation of cysteine S-conjugates 
The key role of mitochondria in xenobiotic bioactiva- 
tion was elucidated uring studies on the selective nephro- 
toxicity of haloalkenes. A multistep, multiorgan bioactiva- 
tion mechanism that explains the selective nephrotoxicity 
and, perhaps, nephrocarcinogenicity of a range of 
haloalkenes was subsequently elucidated. The bioactiva- 
tion of nephrotoxic haloalkenes involves hepatic glu- 
tathione S-conjugate formation, hydrolysis of the glu- 
tathione S-conjugates to cysteine S-conjugates, uptake of 
the S-conjugates by the kidney via amino acid and organic 
anion transport systems, and bioactivation by renal mito- 
chondrial cysteine conjugate/3-1yase. S veral reviews about 
the glutathione- and /3-1yase-dependent bioactivation of 
haloalkenes have appeared [ 10-15]. 
2.1. Bioactivation mechanism 
The microsomal glutathione S-transferases are selective 
catalysts for the biotransformation f haloalkenes to glu- 
tathione S-conjugates (for a review, see [15]). 1,1-Dichlo- 
roalkenes (Fig. 1, la) undergo addition-elimination reac- 
tions to give S-(1-chloroalkenyl)glutathione conjugates, 
which are hydrolyzed to the corresponding S-(l-chloroal- 
kenyl)-L-cysteine conjugates (Fig. 1, 2a), and 1,1-dif- 
luoroalkenes (Fig. 1, lb,c) undergo addition reactions to 
give S-(1,1-difluoroalkyl)glutathione conjugates, which are 
hydrolyzed to S-(1,1-difluoroalkyl)-L-cysteine conjugates 
(Fig. 1, 2b,e). The haloalkene-derived glutathione S-con- 
jugates are excreted in the bile and appear in the portal 
circulation as the intact glutathione S-conjugates or as the 
corresponding cysteine S-conjugates. The y-glutamyltrans- 
ferase-catalyzed hydrolysis of glutathione conjugates yields 
L-cysteinylglycine S-conjugates, which are hydrolyzed to 
the corresponding cysteine S-conjugates by aminopepti- 
dase M or cysteinylglycine dipeptidase [15]. 
The bioactivation of haloalkene-derived cysteine S-con- 
jugates is catalyzed by cysteine conjugate /3-1yase, which 
is identical with glutamine transaminase K [16]. Cysteine 
conjugate /3-1yase is a pyridoxal phosphate-dependent n- 
zyme, which is present in both the cytosol and mito- 
chondria of renal proximal tubular cells, that catalyzes 
both transamination and /3-elimination reactions of cys- 
teine S-conjugates. The transamination of cysteine S-con- 
jugates gives a-keto acids as products and converts the 
enzyme-bound pyridoxal phosphate to pyridoxamine phos- 
phate, which is not competent to catalyze /3-elimination 
reactions, a-Keto acids stimulate the toxicity of cysteine 
S-conjugates, presumably by maintaining the enzyme in 
the pyridoxal phosphate form [ 17,18]. 
The toxicity of cysteine S-conjugates i associated with 
a /3-1yase-catalyzed t-elimination reaction. The critical 
role of the fl-lyase in the bioactivation of cysteine S-con- 
jugates has been demonstrated by use of selective in- 
hibitors and by nonmetabolizable analogs of cysteine S- 
conjugates. Aminooxyacetic acid inhibits a range of pyri- 
doxal phosphate-dependent zymes, including cysteine 
conjugate fl-lyase [19], and blocks the nephrotoxicity and 
cytotoxicity of S-(l,2-dichlorovinyl)-L-cysteine (DCVC) 
[19,20]. Cysteine conjugates blocked with an a-methyl 
group cannot undergo fl-lyase-catalyzed /3-elimination re- 
actions, and the a-methyl analogs of DCVC, S-(2-chloro- 
1,1,2-trifluoroethyl)-L-cysteine a d S-(2-bromo-2-chloro- 
1,1-difluoroethyl)-L-cysteine are not toxic. 
fl-Lyase-catalyzed /3-elimination reactions of cysteine 
S-conjugates afford unstable thiolates as initial products. 
With 1,1-dichloroalkene-derived cysteine S-conjugates 
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Fig. 1. Nephrotoxic haloalkenes ( la-e),  corresponding cysteine S-conjugates (2a-c), products formed by cysteine conjugate /3-1yase (lyase products, 
3a-c), reactive intermediates (4a-e)formed from lyase products, and terminal products (5a-c) formed from reactive intermediates. 
M. W. Anders / Biochimica et Biophysica Acta 1271 (1995) 51-57 53 
(Fig. 1, 2a), l-chloroalkenylthiolates (Fig. 1, 3a) are pro- 
duced. 1-Chloroalkenylthiolates may tautornerize to give 
thioacyl chlorides or may eliminate chloride to give 
thioketenes (Fig. 1, 4a). To explore these possibilities, 
1,2-dichloro-3,3,3-trifluoro-1-propenyl 2-nitrophenyi d sul- 
fide was prepared as a precursor of 1,2-dichioro-3,3,3-tri- 
fluoro-l-propenethiolate [21]. Reaction of the disulfide 
with DABCO and cyclopentadiene i  tetrahydrofuran gave 
the thianorbornene 3-(2,2,2-trifluoro-l-chloroethylidene)- 
2-thiabicyclo[2.2.1]hept-5-ene as a product, indicating that 
a thioketene had formed and undergone a Diels-Alder 
reaction with cyclopentadiene. In the absence of cyclopen- 
tadiene, syn- and anti-2,4-bis(2,2,2-trifluoro-1-chloroethyl- 
idene)-l,3-dithietane w re formed, indicating dimerization 
of the thioketene. Several 1-chloroalkenyl 2-nitrophenyl 
disulfides have been prepared, and all are mutagenic in in 
vitro test systems [22]. Thioketenes may undergo hydroly- 
sis to give haloacetic acids (Fig. 1, 5a) as terminal prod- 
ucts [23]. 
The /3-1yase-dependent biotransformation f bromine- 
lacking cysteine S-conjugates (Fig. 1, 2b) gives 1,1-dif- 
luoroalkanethiolates (Fig. 1, 3b) as initial products. Reac- 
tion of S-(2-chloro-l,l,2-trifluoroethyl)-L-cysteine with 
N-dodecylpyridoxal in cetyltrimethylammonium chloride 
micelles in the presence of benzyl bromide showed the 
formation of benzyl 2-chloro-l,l,2-trifluoroethyl su fide 
[24], indicating that 2-chloro-l,l,2-trifluoroethanethiolate 
was formed and trapped. When diethyl amine was used 
instead of benzyl bromide, N,N-diethyl chlorofluoroth- 
ioacetamide was identified as a product, indicating that the 
intermediate chlorofluorothioacetyl fluoride (Fig. 1, 4b, 
X = CI,F) was formed and trapped. Chlorofluorothioacetyl 
fluoride and difluorothioacetyl fluoride (Fig. 1, 4b, X = F), 
formed from S-(l,l,2,2-tetrafluoroethyl)-L-cysteine, also 
react with protein-bound N'-amino groups of lysine to 
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Fig. 2. Effect of S-(l,2-dichlorovinyl)-L-cysteine (DCVC) on cellular 
adenine nucleotide concentrations. I olated kidney cells were incubated 
with no additions, with DCVC (1 raM) and, or with DCVC (1 mM) and 
aminooxyacetic a id (AOAA, 0.1 mM) for 30 rain at 37 ° C, and ATP, 
ADP, and AMP concentrations were determined by pyridine nucleotide- 
linked enzyme assays. Data are shown as mean _+ S.E., n = 3. Data are 
from Lash and Anders [20]. 
give covalently bound adducts [25-27]. 19F NMR studies 
showed that inorganic fluoride and chlorofluoroacetic acid 
are terminal products of the /3-1yase-catalyzed biotrans- 
formation of S-(2-chloro-l,l,2-trifluoroethyl)-L-cysteine 
[24]. 
Bromine-containing, l l-difluoro-2,2-dihaloethene-de- 
rived cysteine S-conjugates (Fig. 1, 2c) give 2-bromo-2- 
halo-l,l-difluoroethanethiolates (Fig. 1, 3e) as initial prod- 
ucts. The fate of the bromine-containing 1,1-dif- 
luoroethanethiolates differs from that of the bromine-lack- 
ing analogs: glyoxylate (Fig. 1, 4e), rather than dihaloac- 
etates, is formed as a terminal product [28]. Preliminary 
reaction mechanism studies indicate that o~-thiolactones 
may be formed as intermediates during the biotransforma- 
tion of bromine-containing cysteine S-conjugates (M.B. 
Finkelstein, W. Dekant, A.W. Kende, and M.W. Anders, 
unpublished ata). 
2.2. Mitochondrial toxiciO, 
Early studies showed that DCVC inhibits respiration in 
rat and guinea pig kidney slices [29]. DCVC was degraded 
to pyruvate and ammonia by rat liver mitochondria, nd 
semicarbazide blocked both the biotransformation a d in- 
hibition of respiration produced by DCVC [30]. It was also 
demonstrated that the DCVC-induced inhibition of respira- 
tion was associated with inhibition of mitochondrial 2- 
oxoacid ehydrogenases and lipoyl dehydrogenase [31-33]. 
These studies were conducted with rat liver mitochondria, 
but DCVC is not hepatotoxic [34]. (In the liver, kynureni- 
nase catalyzes /3-elimination reactions of cysteine S-con- 
jugates [35].) 
Respiration is, however, also decreased in kidney mito- 
chondria isolated from rats given DCVC [29,31]. Studies 
with isolated rat renal proximal tubular cells showed that 
the cytotoxicity of DCVC was associated with the inhibi- 
tion of cellular oxygen consumption, perturbations in cellu- 
lar adenine nucleotide concentrations, and disturbances in
Ca 2+ compartmentation [20]. Incubation of rat kidney cells 
with DCVC resulted in a large decrease in ATP and total 
adenine nucleotide concentrations and a small increase in 
ADP and AMP concentrations (Fig. 2); the changes in 
adenine nucleotide concentrations were blocked by the 
/3-1yase inhibitor aminooxyacetic a id. The energy charge 
((ATP + I /2ADP)/(ATP + ADP + AMP)) was 0.80 in 
control cells, 0.59 in cells incubated with 1 mM DCVC, 
and 0.71 in cells incubated with 1 mM DCVC and 0.1 mM 
aminooxyacetic acid. Cellular oxygen consumption was 
inhibited in cells incubated with S-(1,2- 
dichlorovinyl)glutathione r DCVC and was blocked by 
acivicin, an inhibitor of y-glutamyltransferase, or 
aminooxyacetic a id, respectively. Also, DCVC reduced 
mitochondrial Ca 2+ sequestration by62%, but did not alter 
microsomal Ca 2 ÷ sequestration r plasma membrane Ca 2+ 
transport. The effect of DCVC on cellular oxygen con- 
sumption with different respiratory substrates was studied 
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Fig. 3. Effect of S-(l,2-dichlorovinyl)-L-cysteine (DCVC) on cellular 
oxygen consumption with different respiratory substrates. Isolated kidney 
cells were incubated in the presence and absence of DCVC (1 mM) with 
glutamate (Glu, 4 mM)+ malate (Mal, 2 mM), with succinate (Succ, 3.3 
raM), or with ascorbate (Asc, 1 mM)+ N,N,N',N'-tetramethylene-p- 
phenylenediamine (TMPD, 0.2 mM) for 2 h at 37 ° C; cellular oxygen 
consumption was measured with a Clark-type lectrode. Data are shown 
as mean + S.E., n = 3. Data are from Lash and Anders [20]. 
(Fig. 3). DCVC had no effect on cellular oxygen consump- 
tion with glutamate and malate or with ascorbate and 
N,N, N',N'-tetramethyl-p-phenylenediamine s substrates, 
but inhibited oxygen consumption with succinate as the 
substrate. 
Further studies showed that DCVC produced a concen- 
tration-dependent reduction in mitochondrial state 3 oxy- 
gen consumption in rat kidney mitochondria in the pres- 
ence of succinate and ADP, but had no effect on state 4 
respiration [36]. In addition, DCVC caused a time-depen- 
dent release of Ca 2÷ and impaired the ability of 
succinate-energized mitochondria to generate a membrane 
potential. In addition, incubation of rat kidney mito- 
chondria with 1 mM DCVC resulted in the leakage of 
malic dehydrogenase into the medium. In addition to the 
effects of DCVC on mitochondrial function and integrity, 
mitochondrial metabolism was also perturbed. Mitochon- 
drial isocitrate, succinate, and aspartate concentrations were 
increased and the concentrations of glutamate and a-keto- 
glutarate were decreased after incubation with 1 mM 
DCVC. The changes in citric acid cycle metabolites were 
accompanied by decreases in the activities of both isoci- 
trate dehydrogenase and succinate:cytochrome c oxido- 
reductase. Mitochondrial glutathione concentrations de- 
creased rapidly and markedly (70%) in mitochondria incu- 
bated with 1 mM DCVC, and the decrease in glutathione 
concentrations was paralleled by an increase in glutathione 
disulfide concentrations. Finally, the decrease in mitochon- 
drial glutathione concentrations was followed by an in- 
crease in lipid peroxidation, as measured by the formation 
of thiobarbituric acid-reactive substances. 
The nephrotoxic conjugate S-(l,2,3,4,4-pentachloro- 
butadienyl)-L-cysteine (PCBC; Fig. 1, 2a, X = C1, CC1 = 
CC12), which is formed by the glutathione-dependent 
bioactivation of hexachlorobutadiene [37], is cytotoxic in 
rat renal epithelial cells [38]. Exposure of rat kidney cells 
to PCBC (0.1 mM) resulted in inhibition of respiration, 
depletion of cellular ATP concentrations, loss of Ca 2+ 
from mitochondria, and the rapid formation of membrane 
blebs. In isolated rat kidney mitochondria, PCBC induced 
a rapid loss of mitochondrial Ca 2÷ and the collapse of the 
mitochondrial membrane potential; these effects were 
blocked by the /3-1yase inhibitor aminooxyacetic acid. 
PCBC also inhibited state 3 respiration with succinate as 
the substrate, indicating that succinate dehydrogenase was 
inhibited. 
PCBC also induces mitochondrial dysfunction in rabbit 
renal proximal tubules [39]. PCBC (0.2 mM) increased 
basal and ouabain-insensitive r spiration in rabbit renal 
proximal tubules after 15 min incubation; this was fol- 
lowed by a decrease in basal, nystatin-stimulated, and 
ouabain-insensitive r spiration and a decrease in glu- 
tathione concentrations after 60 min of incubation. PCBC 
is cytotoxic in rabbit renal proximal tubules, and additional 
studies showed that the initial increase in respiration re- 
sulted from an uncoupling of oxidative phosphorylation, 
whereas the later changes were associated with gross 
mitochondrial damage, including inhibition of state 3 res- 
piration, cytochrome c-cytochrome oxidase, and electron 
transport. Further studies on the uncoupling of mitochon- 
drial oxidative phosphorylation showed that PCBC in- 
creased state 4 respiration with pyruvate + malate or with 
succinate as the substrates and in the presence of the 
FoFI-ATPase inhibitor oligomycin [40]. PCBC induces 
swelling in rabbit renal cortical mitochondria in media 
containing ammonium chloride or sodium chloride, and the 
protonophore carbonyl cyanide p-trifluoromethoxyphenyl 
hydrazone produces similar effects, indicating increased 
mitochondrial proton permeability. These data show that 
PCBC initially uncouples oxidative phosphorylation by 
dissipating the proton gradient. 
Recent studies with fluorescence digital imaging mi- 
croscopy showed that DCVC produced perturbations in 
Ca 2÷ homeostasis n LLC-PK1 cells [41]. LLC-PK1 cells 
incubated with DCVC showed lowered Ca 2÷ concentra- 
tions in the mitochondrial region, and the mitochondria 
could not be stained with rhodamine-123, indicating severe 
mitochondrial damage and the loss of the mitochondrial 
membrane potential. The disturbances in Ca 2+ homeosta- 
sis and mitochondrial function preceded the loss of cell 
viability, as indicated by propidium iodide staining. Addi- 
tional studies showed that DCVC-induced Ca 2+ efflux 
from mitochondria is preceded by oxidation of mitochon- 
drial pyridine nucleotides [42]. The DCVC-induced Ca 2+ 
efflux is blocked by ATP, which inhibits the hydrolysis of 
pyridine nucleotides, and by meta-iodobenzylguanidine, an 
ADP-ribose acceptor. The elevations in cytosolic Ca 2+ 
concentrations are followed by an increase in DNA dou- 
ble-strand breaks, which is associated with the activation 
of Ca 2+- and Mg2+-dependent endonucleases. The in- 
crease in DCVC-induced DNA double-strand breaks is 
followed by increased poly(ADP-ribosylation) of nuclear 
proteins. Inhibitor studies show that DCVC-induced cyto- 
toxicity in LLC-PKI cells is blocked by Quin-2, which 
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chelates cytosolic Ca ~+, by aurintricarboxylic a id, which 
inhibits DNA fragmentation, and by 3-aminobenzamide, 
which inhibits poly(ADP-ribosyl)transferase. 
Mitochondrial DNA is also as target for haloalkene-de- 
rived cysteine S-conjugates. Metabolites of [1,2,3,4- 
]4C]hexachlorobutadiene, which is metabolized to 
[l,2,3,4-butadienyl-~4C]PCBC, become covalently bound 
(2795 _ 410 pmol ~4C/mg DNA) to kidney mitochondrial 
DNA (mtDNA), whereas little binding to renal nuclear 
DNA or to hepatic nuclear DNA or mtDNA was detected 
[43]. PCBC also inhibits chloramphenicol-sensitive mito- 
chondrial protein, mtDNA, and mtRNA synthesis, and this 
effect is inhibited by aminooxyacetic a id [44]. In rat renal 
mitochondria incubated with PCBC, much of the high- 
molecular-weight mtDNA was degraded, and the super- 
coiled form was converted to the relaxed circular form and 
to shorter linear fragments. 
In summary, a range of haloalkene-derived, nephrotoxic 
cysteine S-conjugates undergo mitochondrial bioactivation 
and induce mitochondrial dysfunction. Indeed, mitochon- 
drial dysfunction is the hallmark of cysteine S-conjugate- 
induced cytotoxicity. The steps leading from mitochondrial 
dysfunction to cell death have not been elucidated, but 
recent studies indicate that mitochondrial HSP60 and a 
HSP70-1ike protein (mortalin) are targets for reactive inter- 
mediates formed from cysteine S-conjugates [45]; hence, 
perturbations in vital housekeeping functions may be an 
important step in conjugate-induced cell death. 
3. Mitochondriai bioactivation of 4-thiaalkanoates 
Structure-toxicity studies with DCVC showed that the 
analog lacking the carboxy group, i.e., S-(1,2-dichloro- 
vinyl)-2-mercaptoethylamine, was not toxic, whereas the 
analog lacking the amino group, i.e., 5,6-dichloro-4-thia- 
5-hexenoic acid (Fig. 4, 1, DCTH; also termed S-(l,2-di- 
chlorovinyl)-3-mercaptopropionic acid) was more toxic 
than DCVC and also induced mitochondrial dysfunction 
by inhibiting 2-oxoacid ehydrogenases [29,31,32]. 
Studies were undertaken to test the hypothesis that 
DCTH is bioactivated by the enzymes of fatty acid /3- 
oxidation: the initial step in the bioactivation of DCTH 
may be CoA thioester formation to give DCTH-CoA (Fig. 
4, 1). DCTH-CoA may be a substrate for the medium-chain 
acyl-CoA dehydrogenase and give 5,6-dichloro-4-thia- 
2,5-hexadienoyl-CoA (Fig. 4, 2) as a product. Enoyl-CoA 
2 may be a substrate for enoyl-CoA hydratase (crotonase) 
and yield the thiohemiacetal 5,6-dichloro-4-thia-3-hy- 
droxy-5-hexenoyl-CoA (Fig. 4, 3). Thiohemiacetal 3 may 
eliminate 1,2-dichloroethenethiolate (Fig. 4, 4) to afford 
malonylsemialdehyde-CoA (Fig. 4, 6). Ethenethiolate 4 is 
the same product that is presumably formed by the /3- 
lyase-catalyzed /3-elimination reaction of DCVC (Fig. 1, 
3a, X = H, CI). 4-Thiaoctanoic acid is a substrate for the 
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Fig. 4. Bioactivation of 5,6-dichloro-4-thia-5-hexenoyl-CoA (1). MCAD, 
medium-chain acyl-CoA dehydrogenase; 2, 5,6-dichloro-4-thia-2,5- 
hexadienoyl-CoA; 3, 5,6-dichloro-3-hydroxy-4-thia-5-hexenoyl-CoA; 4, 
1,2-dichloroethenethiolate; 5, malonylsemialdehyde-CoA; 6, acryoyl- 
CoA; 7, chlorothioketene; 8, 3-hydroxypropionyl-CoA; 9, chloroacetic 
acid. 
that the 4-thiaalkanoate DCTH may also undergo bioacti- 
vation by the pathway. 
3.1. Bioactivation mechanism 
DCTH-induced time- and concentration-dependent cyto-
toxicity in isolated rat hepatocytes [48]. The hypothesis 
that DCTH is bioactivated by the enzymes of fatty acid 
fl-oxidation was studied with chain-length analogs of 
DCTH. The 5-thia and 7-thia analogs of DCTH (Fig. 5, 
DCTHep and DCTN, respectively), elongated by addition 
of one or three methylene units, were not cytotoxic at 
concentrations 20-fold higher than DCTH, whereas the 
6-thia analog of DCTH (Fig. 5, DCTO), elongated by 





Con DCTHep DCTN PCTOD 
DCTH DCTO CTFTH 
Fig. 5. Cytotoxicity of DCTH (50 /xM), 6,7-dichloro-5-thia-6-heptenoic 
acid (DCTHep, l raM), 7,8-dichloro-6-thia-7-octenoic acid (DCTO, 50 
/xM), 8,9-dichloro-7-thia-8-nonenoic ac d (DCTN, 1 mM), 6-chloro- 
5,5,6-trifluoro-4-thiahexanoic acid (CTFTH, 100/xM), and 5,6,7,8,8-pen- 
tachloro-4-thia-5,7-octadienoic acid (PCTOD, 50 /xM) in isolated rat 
hepatocytes; Con = control. Data are shown as mean_+ S.D., n = 3. Data 
are from Fitzsimmons and Anders [48]. 
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(Fig. 5). These data indicate that the 6-thia analog DCTO 
undergoes one cycle of/3-oxidation to give DCTH, which 
is cytotoxic. In contrast, he 5- and 7-thia analogs DCTHep 
and DCTN cannot form thiohemiacetals that eliminate 
1,2-dichloroethenethiolate and are, therefore, not cytotoxic. 
Moreover, the 4-thia analogs of the cysteine S-conjugates 
S-(2-chloro-l,l,2-trifluoroethyl)-L-cysteine (Fig. 5, 
CTFTH) and PCBC (Fig. 5, PCTOD) are cytotoxic in rat 
hepatocytes, indicating that /3-oxidation results in the elim- 
ination of a toxic metabolite. The cytotoxicity of DCTH 
was blocked by sodium benzoate, which depletes CoA 
concentrations, and octanoic acid, which is an alternative 
substrate for the medium-chain acyl-CoA dehydrogenase; 
these observations support a role for /3-oxidation in the 
toxicity of DCTH. 
The bioactivation mechanism for DCTH outlined above 
has recently been validated (Fitzsimmons, M.E., Thorpe, 
C. and Anders, M.W., unpublished ata). Incubation of 
DCTH-CoA with purified medium-chain acyl-CoA dehy- 
drogenase in the presence of ferricenium hexafluorophos- 
phate as an electron acceptor lead to the formation of 
5,6-dichloro-4-thia-2,5-hexadienoyl-CoA (Fig. 4, path a, 
2). Enoyl-CoA hydratase-catalyzed hy ration of enoyl-CoA 
2, which would be expected to give an intermediate hio- 
hemiacetal (Fig. 4, 3), lead to the formation of mal- 
onylsemialdehyde-CoA (Fig. 4, 5) and chloroacetic acid 
(Fig. 4, 9); chloroacetic acid was presumably formed by 
hydrolysis of the 1,2-dichloroethenethiolate-derived 
chlorothioketene (Fig. 4, 7 ~ 9). When DCTH-CoA was 
incubated with the acyl-CoA dehydrogenase in the absence 
of an electron acceptor, 3-hydroxypropionyl-CoA (Fig. 4, 
8) was identified as a product. In the absence of an 
electron acceptor (Fig. 4, path b), DCTH-CoA apparently 
eliminates 1,2-dichloroethenethiolate 4 o give acryoyl- 
CoA (Fig. 4, 6), which is hydrated to give 3-hydroxypro- 
pionyl-CoA. Also, in the absence of an electron acceptor, 
DCTH-CoA rapidly and irreversibly inactivates the 
medium-chain acyl-CoA dehydrogenase. 
3.2. Mitochondrial toxicity 
The mitochondrial toxicity of 4-thiaalkanoates has not 
been explored in detail, but earlier studies indicate that 
mitochondria are a site of action [29,31,32]. Also, DCTH 
is activated by the enzymes of fatty acid /3-oxidation, 
which are located in mitochondria. In studies in isolated rat 
hepatocytes, DCTH decreased cellular ATP concentra- 
tions, increased ADP and AMP concentrations, decreased 
the energy charge, and decreased cellular glutathione con- 
centrations, but had no effect on glutathione disulfide 
concentrations [48]. These perturbations in cellular adenine 
nucleotide homeostasis are also consistent with a role for 
mitochondrial s a critical cellular target. 
In vivo studies also point to mitochondria as a target for 
DCTH [49]. Fatty acid /3-oxidation is reduced in both liver 
and kidney mitochondria of DCTH treated rats, and 
medium-chain acyl-CoA dehydrogenase activity is reduced 
in rat liver mitochondria incubated with DCTH. Also, a 
prominent feature of DCTH-induced toxicity is hypo- 
glycemia; this may be the result of impaired gluconeo- 
genesis, which is a consequence of decreased fatty acid 
/3-oxidation. Methylenecyclopropylacetic acid, a metabo- 
lite of hypoglycin A, inactivates the short- and medium- 
chain acyl-CoA dehydrogenases and causes hypoglycemia 
[50]. Finally, organic aciduria was observed in DCTH- 
treated rats. Increased urinary lactic acid concentrations 
may be the result of inhibition of the pyruvate dehydro- 
genase complex [51 ]. 
4. Biomedical consequences of mitochondriai bioactiva- 
tion of cysteine S-conjugates and 4-thiaalkanoates 
Mitochondrial bioactivation accounts for the observed 
cytotoxicity of a range of cysteine S-conjugates in isolated 
kidney cells or in kidney-derived cell lines (i.e., LLC-PK1). 
The organ-selective toxicity of haloalkene-derived cysteine 
S-conjugates i  associated with the ability of the kidney to 
transport and concentrate amino acids and amino acid 
analogs [52] and with the presence of /3-1yase in the 
kidney [16]. Moreover, several haloalkenes are nephrotoxic 
[53,54], and the glutathione-dependent bioactivation of 
these compounds explains their selective nephrotoxicity. In 
addition, the /3-1yase-dependent bioactivation of cysteine 
S-conjugates has been implicated in the nephrocarcino- 
genicity of chloroalkenes [55]. 
The target-organ selective toxicity of cysteine S-con- 
jugates amounts to a delivery system for toxic metabolites, 
and, in principle, the same system could be exploited to 
deliver drugs to the kidney. This possibility has been 
successfully tested: S-(6-purinyl)-L-cysteine undergoes /3- 
lyase-dependent metabolism and produces elevated con- 
centrations of 6-mercaptopurine  the kidney [56]. 
The bioactivation of 4-thiaalkanoates has potential for 
the organ- and organelle-selective delivery of drugs. The 
mitochondrial location of the enzymes of fatty acid /3- 
oxidation indicates that 4-thiaalkanoate-based drugs or 
antioxidants could be exploited to release selectively drugs 
or antioxidants in mitochondria. Also, if the kidney selec- 
tivity of DCTH can be extrapolated to other 4- 
thiaalkanoate-based drugs, it may be possible to deliver 
drugs to renal mitochondria. These possibilities merit ex- 
amination. 
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